Meningococcal conjugate vaccine in adolescents and children

Clinical Pediatrics

Volumn 44, Issue 6, 2005, Pages 479-489

  Pichichero, Michael E ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE; POLYSACCHARIDE VACCINE;

ADOLESCENT; ANOREXIA; B LYMPHOCYTE; CHILD; CLINICAL TRIAL; COLLEGE; DIARRHEA; DROWSINESS; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ERYTHEMA; FATIGUE; FEVER; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; IMMUNOSTIMULATION; MENINGOCOCCOSIS; MORTALITY; NASOPHARYNX; NEISSERIA MENINGITIDIS; NONHUMAN; PAIN; REVIEW; SCHOOL CHILD; T LYMPHOCYTE ACTIVATION; URTICARIA; VOMITING;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MIDDLE AGED; UNITED STATES;

EID: 22044438720     PISSN: 00099228     EISSN: None     Source Type: Journal    
DOI: 10.1177/000992280504400603     Document Type: Review

References (30)

1. Rosenstein N, Perkins B, Stephens D, et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis. 1999;180:1894.
2. CDC. Summary of Notifiable Diseases - United States, 2001. MMWR. 2003;50(53).
3. Schuchat A, Robinson K, Wenger J, et al. Bacterial meningitis in the United States in 1995. N Engl J Med. 1997;337:970.
4. CDC. Prevention and control of meningococcal diseuse. Recommendations of the Advisory Committee on Immunization Practices (AICP). MMWR. 2000;19(RR-7):1.
5. Lingappa J, Roscnstein N, Zell E, et al. Surveillance for meningococcal disease and strategies for use of conjugate meningococcal vaccines in the United States. Vaccine. 2001;19:4566.
6. CDC. Active bacterial core surveillance (ABCs) Report, Emerging Infections Program Network, Neisseria meningitidis 2000. ABCs/NETSS 2002.
7. Rosenstein N, Levine O, Taylor J, et al. Efficacy of meningococcal vaccine and barriers to vaccination. JAMA. 1998;279(6):435.
8. Harrison LH, Dwyer DM, Maples CT, et al. Risk of meningococcal infection in college students. JAMA. 1999;281 (20):1906.
9. Lepow M, Perkins B, Hughes P, et al. Meningococcal vaccines. In Plotkin S (ed): Vaccines, 3rd ed. Philadelphia: WB Sannders, 2003; Chapter 34.
10. Cecsay S, Allen S, Menon A, et al. Decline in meningococcal antibody levels in African children 5 years after vaccination and the lack of an effect on booster immunization. J Infect Dis. 1993;167:1212.
11. Mitchell L, Ochnio J, Glover C, et al. Analysis of meningococcal serogroup C-Specific antibody levels in British Columbian Children and Adolescents. J Infect Dis. 1996;173:1009.
12. Lieberman J, Shiu S, Wong V, et al. Safety and inuminogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in small children - A randomized controlled trial. JAMA. 1996;275(19):1499.
13. Campagne G, Barba A, Fahre P, et al. Safety and immunogenicity of three doses of a Neisseria meningitidis A + C diphtheria conjugate vaccine in infants from Niger. Pediatr Infect Dis J. 2000;19:144.
14. Leach A, Twamasi P, Kuman S, et al. Induction of immunologic memory in gambian children by vaccination in infancy with group A plus group C meningococcal polysaccharide-protein conjugate vaccine. J Infect Dis. 1997;175:200.
15. MacLennan J, Obaro S, Decks J, et al. Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunisation during early childhood. Vaccine. 1999;17(23-24):3086.
16. Richmond P, Borrow R, Miller E, et al. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis. 1999;179:1569.
17. Borrow R, Goldblatt D, Andrews N, et al. Antibody persistence and immunological memory at age 4 years alter meningococcal group C conjugate vaccination in children in the United Kingdom. J Infect Dis. 2002;186:1353.
18. McVernon J, Maclennan J, Buttery J, et al. Safety and immunogenicity of meningococcus serogroup C conjugate vaccine administered as a primary or booster vaccination to healthy four-year-old children. Pediatr Infect Dis J. 2002;21:747.
19. MacLennan J, Obaro S, Decks J, et al. Immunologic memory of 5 years alter meningococcal A/C conjugate vaccination in infancy. J Infect Dis. 2001;183:97.
20. Zhang Q, Pettitt E, Burkinshaw R, et al. Mucosal immune responses to meningococcal conjugate polysaccharide vaccines in infants. Pediatr Infect Dis J. 2002;21:209.
21. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine. 2001;20(Suppl 1):S58.
22. Maiden MC, Stuart JM. Carriage of serogroup C, meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet. 2002;359(9320):1829.
23. Ramsay M, Andrews N, Trotter C, et al. Herd immunity from meningococcal serogroup C conjugate vaccination in England: Database analysis. BMJ. 2003;326:365.
24. Trotter CL, Andrews NJ, Kaczmarski KB, et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet. 2004;364(9431):365.
25. Balmer P, Borrow R, Miller E. Impact of meningococcal C conjugate vaccine in the UK. J Med Microbiol. 2002;51(9):717.
26. Pichichero M, Casey J, Blatter M, et al. Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children. Pediatr Infect Dis J. 2005;24(1):57.
27. Granoff DM, Harris SL. Protective activity of group C anticapsular antibodies elicited in two-year-olds by an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine. Pediatr Infect Dis J. 2004;23(6):490.
28. Pichichero M, Casey J, Papa T, et al. A tetravalent (A, C, Y, and W-135) meningococcal diptheria toxoid conjugate vaccine, MCV-4, established immune memory in 2-3-year-old children after a single dose. Presented at the 44th Intersciencc Conference on Antimicrobial Agents and Chemotherapy, 2004; Washington, DC.
29. Keyserling H, Papa T, Bybel M. A comparative trial of the safety and immunogenicity of an experimental tetravalent meningococcal (A, C, Y, A-135) diphtheria conjugale vaccine vs. a licensed meningococcal (A, C, Y, and W-135) polysaccharide vaccine in healthy adolescents. Presented at the 43rd Intersciencc Conference on Antimicrobial Agents and Chemotherapy, 2003; Chicago, IL.
30. Keyserling H, Rothstein E, Blatter M, et al. Augmentation of the immune response to a quadrivalent meningococcal (A, C, Y, W-135) diphtheria conjugate vaccine (MCV-4) by co-administration with tetanus-diphtheria vaccine (Td) in healthy adolescents. [Abstract 1044]. Presented at the 42nd Annual Meeting of Infectious Diseases Society of America, 2004; Boston, MA.